Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.53 |
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10441796 | 1.00 | ITGB3 (0.60) | ITGB3ITGA2BABCB1LDHAPPARG | |
| SCHEMBL14493013 | 1.00 | ITGB3 (0.60) | ITGB3ITGA2BABCB1LDHAPPARG | |
| SCHEMBL2494968 | 0.91 | ITGB3 (0.59) | ITGB3ITGA2BABCB1P2RX7KMT2A | |
| SCHEMBL31739224 | 0.91 | ITGB3 (0.59) | ITGB3ITGA2BABCB1P2RX7KMT2A | |
| SCHEMBL8067076 | 0.91 | ITGB3 (0.59) | ITGB3ITGA2BABCB1P2RX7KMT2A | |
| SCHEMBL2968658 | 0.91 | ITGB3 (0.59) | ITGB3ITGA2BABCB1P2RX7KMT2A | |
| SCHEMBL10790060 | 0.90 | ITGB3 (0.66) | ITGB3ITGA2BABCB1PPARGPPARA | |
| SCHEMBL26654521 | 0.90 | ITGB3 (0.58) | ITGB3ITGA2BABCB1P2RX7KMT2A | |
| SCHEMBL26654515 | 0.90 | ITGB3 (0.58) | ITGB3ITGA2BABCB1P2RX7KMT2A | |
| SCHEMBL6378199 | 0.88 | ITGB3 (0.58) | ITGB3ITGA2BABCB1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030279-B2 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030279-B2 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-10-04 | — | — | US | disclosed |
| US-7678765-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2010-03-16 | — | — | US | disclosed |
| US-7678765-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2010-03-16 | — | — | US | disclosed |
| US-7678765-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2010-03-16 | — | — | US | disclosed |
| EP-1613338-A4 | TAMANDARIN ANALOGS AND FRAGMENTS THEREOF AND METHODS OF MAKING AND USING | JOULLIE MADELEINE M (US) | 2009-06-24 | — | — | EP | disclosed |
| EP-1294747-B1 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR SA (ES) | 2008-04-30 | — | — | EP | disclosed |
| US-7348310-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2008-03-25 | — | — | US | disclosed |
| US-7348310-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2008-03-25 | — | — | US | disclosed |
| US-7348310-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2008-03-25 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CENTER FOR TECHNOLOGY TRANSFER (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CENTER FOR TECHNOLOGY TRANSFER (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CENTER FOR TECHNOLOGY TRANSFER (US) | 2007-06-28 | — | — | US | disclosed |
| EP-1613338-A2 | TAMANDARIN ANALOGS AND FRAGMENTS THEREOF AND METHODS OF MAKING AND USING | Joullie, Madeleine M. (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004084812-A2 | TAMANDARIN ANALOGS AND FRAGMENTS THEREOF AND METHODS OF MAKING AND USING | JOULLIE MADELEINE M (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040097413-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097413-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | MCL1, PML, APLNR | ITGB3 3676/4885ITGA2B 3316/4885ABCB1 2760/4885 |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | MCL1, APLNR, PAICS | ITGB3 4341/4885ITGA2B 3677/4885ABCB1 2724/4885 |
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | FOXM1, F3, RB1 | ITGB3 2651/4885ITGA2B 3010/4885ABCB1 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.